Until now only possible to buy a bond navigation Internet could be monthly 250 MB or 500 MB per month, although with limited functionality is not available BlackBerry. So that users with these devices were very attracted if your current carrier if they offered and or were hired, and given that the operator. Primarily aimed at young people wishing to speak at a very cheap or free if you have your friends with the only condition to make a minimum recharge every 30 days. You can visit here for details information about blackberry bold 9790 unlock.

Thanks to BlackBerry service, users who employ this data rate will benefit from native applications RIM such as BlackBerry Messenger, BlackBerry Mailthe Explorer. With all this, we must not forget that the price is much lower compared to the greats of the phone, so we can find something.

Although not yet revealed any price or any exact date, all those seeking a unlock blackberry 9380 service complete, so you just have to wait for it to give more details.

n addition, by having BlackBerry (BlackBerry Internet Service)have begun to sell and subsidize through Your Store these terminals, although with few-mode models postpaid plan and to benefit from a stay of 18 or 24 months at a price of 15€ per month, which include:

– 3000 minutes of calls per month and 3,000 SMS to all numbers.
– 100 minutes of calls and 100 SMS per month to other operators.
– Free navigation .
– Access to Mail and BlackBerry Messenger indefinitely.
– 50 MB of Internet access outside of these applications.

The next Milestone shares more than one air with Motorola Razr. In terms of design, are the same size, material and style. It seems that they will also share specifications: front camera, 1080p video recording, 4G connectivity LTEExit miniHDMI. If you want to know brief information about unlock motorola droid razr you can visit here.

The five-row sliding keyboard does not stick to the screen on one side (as in 1 and 3), and apparently going to be backlit. The battery is not removable. Know the chipset, but surely move fluently software: Motorola Android 2.3.5 and Blur.

The new terminal features Motorola’s Android LTE connectivity, and has been featured on the very day he has to do with Samsung and Google the new Galaxy Nexus. The orchestra of all these events takes you recall that Google, Motorola owns and master of ceremonies for the presentation tonight with Ice Cream Sandwich. If you want to unlock motorola xt532 you can visit here.

The back is made of special material, Kevlar fiber, which gives it rigidity and lightness at the same time. The chassis is steel and aluminum, and features a splash layer, and Gorilla Glass technology on your screen.

Something as common on newer phones Motorola is betting on the QHD resolution (960 × 540pixeles) than for 4.3-inch are fine, but we’ll see how Samsung and LG are when you go up the ante with their HD displays.

As for the camera, the Motorola Razr has a module 8 megapixels accompanied by flash LED, and is capable of recording video in 1080p format. In the front we have a 1.3 megapixel front camera for video calls capable of supporting 720p format.

Motorola Razr bet on Texas Instruments:

As usual in Motorola, and like Google, it is responsible for giving life to the Razr chipset, namely we have a OMAP Dual-Core 4400 1.2 GHz. The battery to power all of this is 1,800 mAh.

It is also noteworthy that we 1GB of RAM, And 16GB of internal memory. In terms of connectivity, Bluetooth 4.0 releases, connector and has support miniHDMI Glonass. Waiting for Ice Cream Sandwich, we have to content themselves with the latest we have on the market, Gingerbread in version 2.3.5.

This rare syndrome is due to alterations of a gene, called OCRL1, which contains the information for an enzyme essential for the intracellular trafficking and transport of substances. Since this gene is located on the X chromosome, males are generally to be affected, while females are carriers. The disease is present at birth with congenital cataracts and severe hypotonia, then glaucoma, mental retardation and motor development, seizures, behavioral problems, kidney problems. Just renal failure is a symptom that puts at risk the lives of patients suffering from this disease, for which there is currently no cure.

The transport of substances to and from the cell is a very complex system that, as the same De Matteis has recently shown in a review in The New England Journal of Medicine, involved more than 2000 proteins and is disrupted in at least 80 different genetic disorders (including various forms of hereditary spastic paraplegia and muscular dystrophy).


In this work, researchers have clarified TIGEM for the first time that the defect in OCRL1 results, in the kidney, in a non-reabsorption of protein in the urine.

“By studying kidney cells in culture,” says the researcher, “we have clarified one of the molecular mechanisms underlying this phenomenon. OCRL1 normally has the task of directing the traffic of substances that picks up from outside the cell, through a process called endocytosis: in particularly in the kidneys is responsible for a specific chemical signal for the absorption of proteins from the urine that should not be eliminated. When OCRL1 is altered, however, the transport system is jammed and you have a chronic accumulation of protein in the urine. For As can be pharmacologically control, proteinuria over time leads to kidney failure, which is the main cause of early death for these patients”.

This discovery opens the door to a possible drug therapy to counteract renal damage. As the researcher explains, “having shown what are the specific chemical signals that govern this process can go in search of drugs able to balance the traffic of substances in the kidney. In parallel, thanks to the sophisticated tools available here at the microscope can TIGEM analyze thousands of compounds at a time, looking for those with the desired effect: once identified we can go to study the mechanism by which exercise that action. Proceeding along these two roads we hope to arrive as soon as possible to an effective treatment against kidney damage”.

The working group has demonstrated that inactivation of the receptor type 2 corticotropin-releasing factor (CRF2) eliminates the signs of physical and negative affective states observed in patients addicted to opiate drugs following the suspension of their engagement. However, the lack of this receptor does not affect the major physiological functions that are implemented by the human body in response to stressful events.

The corticotropin-releasing factor is a neuropeptide that coordinates behavioral responses, neuroendocrine and autonomic nervous system stress, acting through two types of receptors, CRF 1 and CRF2.

“With the inactivation of the receptor CRF2 – says Dr. Francesco Papaleo – we got a block of dysphoric states, ie the psychological malaise, anhedonia and states, so the lack of feeling of pleasure induced by abstinence from opiate drugs. These negative affective states are among the main factors responsible for the chronicity of addiction. So, to understand what is the mechanism to stop or alleviate these negative symptoms opens up the possibility to create drugs to facilitate the exit from drug addiction”.

In fact, dependence on opiate drugs such as heroin, morphine or opium, is a chronic disease characterized by a high recurrence rate, which impacts heavily on health systems worldwide. In addition, some studies indicate a strong increase in recreational use of opioid drugs in adolescents, indicating that the incidence of drug could increase dramatically in coming years.

“If it is true that today there are drugs that reduce the withdrawal symptoms of acute opiate drugs such as methadone or buprenorphine, continues Dr. Angelo Contarino, they activate the same receptors that are stimulated by drugs opiates, resulting in a strong dependence on themselves. In fact, very often determines their interruption the “fallout” from the so-called “street” drugs, like heroin. So, to find an alternative therapy to drugs by “replacing” such as methadone or buprenorphine remains a major goal of research on addiction to opiate drugs”.

Researchers from four institutions led by Lorenz Studer of the American Memorial Sloan-Kettering Cancer Center in New York, have developed a new method to turn human embryonic stem cells into neurons in the brain. Transplanted into animals, cells are able to survive and integrate into the nervous system producing dopamine, the substance whose deficiency is the basis of diseases such as Parkinson’s disease.

The important work is co-funded by NEUROSTEMCELL, a research consortium that includes 16 partners from 6 European countries and one (Studer’s research group) in the United States. The consortium, funded by the EU, aims to develop the application of stem cells to treat Parkinson’s disease and Huntington’s disease and is coordinated by Elena Cattaneo, director of the Center for Stem Cell Research, University of Milan.

As is well known, embryonic stem cells can give rise to each of more than 200 cell types that make up our body. American researchers have developed an innovative system to direct the differentiation of these cells, guiding the transformation in dopaminergic neurons (dopamine-producing), ie the class of nerve cells that degenerate in the brains of patients with Parkinson’s disease.

For over a decade producing cells in the laboratory similar to dopaminergic neurons from human stem starting, but the neurons “regenerated” have so far been unable to survive and integrate into the brain after transplantation, and have the dangerous tendency to grow in an uncontrolled manner, with the risk of cancer. To overcome these limitations Studer and colleagues used the new knowledge on the development of the nervous system leading the genetic program of stem cells to transform into “authentic” dopaminergic cells, virtually indistinguishable from those present in the human brain.


The researchers then transplanted the cells in three animal models with Parkinson’s disease: mice, rats and then monkeys. The transplanted cells showed good survival skills and long-term integration, behaving like normal dopaminergic cells. Also, do not proliferate in an uncontrolled way, thus averting the risk of cancer. In mice and rats with Parkinson’s, finally, the transplant has countered some of the symptoms of the disease.

The availability of these new cells help the research base and is the first step towards future clinical applications. The authors point out, however, that this is still laboratory results, and no one can say if and when they are applicable to patients.

Studer explains: “We are now working to produce these cells under conditions suitable for clinical studies. It ‘a process that requires complex adaptations, the first studies on patients who can not start in 3 or 4 years”.

Elena Cattaneo, project coordinator NEUROSTEMCELL declares: “This work represents an important step towards the possible clinical applications of human embryonic cells.” Cattaneo added that the results of the team of Studer “pose a challenge to Europe with regard to future legislation and competitiveness in this field,” referring to the limitations of human embryonic stem cell research, and the recent European Court of Justice, which prohibited the patenting of inventions derived from them.

RNAi

To discover for the first time how this happens on a global scale in the genome is Valerio Orlando, Dulbecco Telethon Institute researcher who works at the Saint Lucia Foundation of Rome: cells respond to crises directly modulating the activity of genes due to interference RNA, a mechanism very conserved in evolution, which in 2006 also earned its discoverers the Nobel Prize to Andrew Fire and Craig Mello. The study, funded by Telethon and the Italian Association of Cancer Research, with funding from the Ministry of Foreign Affairs (Projects of great significance Italy-Japan), has merited publication in Nature.

The RNA – which stands for ribonucleic acid – is a molecule similar to DNA in the cell that performs numerous tasks, including that of messenger, the cell produces, starting from the DNA strands of RNA that act as “mold” for the translation into proteins. RNA interference is a mechanism common to almost all living organisms, even simple ones such as yeast, which has evolved primarily to protect cells from viruses, the main source of foreign RNA. The cell recognizes these molecules as foreign, is alert and reduces them into smaller pieces to eliminate them, thus preventing viral proteins are produced.

In the course of this mechanism has also been adopted to suppress the production of cellular proteins is not necessary at a given time, thus controlling protein synthesis in an order: small RNA products from portions recognize specific cell in the “messenger RNA” and decreed thus destroying them.

Recently it was discovered that, contrary to what was thought, only 5 percent of the genome produces information subsequently translated into proteins. In fact, most of the RNA product appears to act at a level higher than the DNA, through mechanisms that researchers call “epigenetic” and that allow cells to retain their identity over time. The study of these mechanisms is important to understand not only how a cell acquires its peculiar characteristics, as well as the loss of this identity can result in pathological states such as cancer and degenerative diseases.

“Until now it was thought that the regulation of RNA levels of protein and then happen in the cytoplasm, the cellular compartment in which the messenger RNA is converted into proteins,” says Orlando. “In this work we demonstrated for the first time that this also occurs in the nucleus where the DNA resides: it is a” comprehensive plan “of gene regulation completely new, long pursued by researchers around the world. According to this plan, in case of “crisis” – sudden changes in temperature and available nutrients, or changes in the course of development – the cell uses the machines that produce small RNA within the nucleus to directly inhibit the production of RNA to the source and adapted so environmental conditions “.

“Our results, obtained by studying the cells of fruit flies, are of great interest,” explains David Crown, a researcher at the University of Palermo Telethon, funded by the Armenise-Harvard Foundation, which took part in the study: “in the case of diseases excessive or reduced production of certain proteins, in fact, these small nuclear RNA could be used to modulate the expression of genes in a stable manner by adjusting the amount of protein produced, without necessarily working on the genetic defect responsible for the disease. ”

To get to the bottom of this new role of small RNA, the researchers are now working to understand in detail the mechanism of action in human cells. Orlando concludes: “the discovery of this mechanism represents a fundamental step to understanding how small RNAs can be used for therapeutic purposes on the operating level” epigenetic “rather than genetic.”

Which drugs can be distinguished:

Drugs similar substances are also formed by the brain itself. Even in medicine are drugs, for example, used to relieve pain. The application field is still much more extensive. The best known, however, is the so-called abuse of illegal drugs such as opiates (cocaine, amphetamines), cannabis (hemp), hallucinogens (mescaline, LSD) and em-pathogen substances (ECSTASY). Since the different types of drugs include various drugs, and its effect on the brain is different.

The effect of nicotine on the brain:

The best known, and by the state through the collection of taxes, legitimate drug is nicotine, although it:

– It reaches the brain within 10 seconds
– There one type of receptor binds the transmitter acetylcholine
– The key function of the natural neurotransmitter copied

As a result, there is an increased stimulus of the receptor, in contrast to the natural neurotransmitter. In addition, nicotine binds only a certain type of receptor, resulting in an unbalanced and biased amplification effect. The natural neurotransmitter binds, in contrast, different receptor types.

The addiction is caused by the much higher efficiency and the flooding of the type of receptor to which nicotine is down-leader. Followed by a familiarization with the dose increased the body demands more for more. Consequence is the increase in consumption addiction.

The effect of heroin on the brain:

The morphine was named after the god of dreams and of sleep, Morpheus. By chemical modifications, it is processed to the known drug heroin. As can be deduced therefore, this stuff makes you sleepy and relaxed consumers.

In the field of medical drug used to relieve very severe pain. The patient is treated for the pain still was, but he is by the brain only rated as marginal and fined. This is dangerous but that morphine acts directly inhibitory to the respiratory center in the brain stem. The result is a slowing of respiratory rate. In an overdose, it is usually a respiratory arrest followed by suffocation of narcotics users.

Morphine achieves its broad impact in that it can simulate a number of different neurotransmitters by its ingredients. It transmitter substances such as endorphins, enkephalins and dynorphin similar strong enough to occupy the corresponding synapses. It blocks the contact points of natural messengers. And this leads consequently to reduce the physical pain threshold.

Cocaine and its effects on the brain:

Through the use of cocaine you get that feeling that you have no hunger and no more and more tired. In contrast to the aforementioned types of drugs that works out of the coca bush cocaine derived indirectly on the brain and its functioning mechanisms.

It does not block the synapses before the natural neurotransmitter (noradrenaline) special to those whose whereabouts. It simply extends the time. However, it is not only the time is extended, cocaine increases the concentration of endogenous transmitter substance noradrenaline. This affects also affects those areas of the brain, which are controlled in important bodily functions, such as the increase in heart rate and blood pressure. A high risk of stroke is the result.

Ecstasy also is not harmless!

A fourth transmitter system, serotonin is affected by the addictive drug ecstasy. Ecstasy, belonging to the hallucinogens, the brain causes a feeling of disembodiment on the one hand, on the other hand, an overwhelming feeling euphoric.

Ecstasy causes the body an enormous payout to serotonin, which leads the brain to a veritable flood. However, this has implications for the human metabolism and temperature regulation system. Furthermore, the use of ecstasy leads to hyperactivity with a tremendous urge to move. Therefore, it is also known as a party drug. Repeated use of ecstasy leads to the death on the duration of certain groups of neurons that form a connection from the brain stem to higher brain regions. This is likely to have a material impact on fundamental brain functions such as sleep.

Due to the long-term use of ecstasy occurs in the brain but also to a depletion of serotonin stores, which can result in depression, and then up to the suicide of drug users.

Many connections are still open:

The brain is a very special functional mechanism of biological, chemical and electrical processes that can interfere with the drugs in a variety of ways. The ecstasy through the increased secretion transmitter to an exhaustion of a stock that cocaine increases the binding of endogenous substances and duration of both nicotine and morphine copy and simulate certain natural compounds as neurotransmitters.

The full extent of the effects on the brain and the entire human body is also still not known. Parts of the research are very concerned with the identification of correlations between the self and the physical consequences of taking or changes.

In summary, it can be said that the lead intake of drugs over a period of time not only to physical and psychological dependence but also more far-reaching negative effects on the body and has in most cases, unhealthy and life-shortening effects.

The Court of Justice rejects the patent application of a treatment against Parkinson’s disease that involved the use of human embryos. On 19 December 1997, German researcher Oliver Brustle had patented a treatment that involved the use of embryonic stem cells for five days after fertilization. The product obtained from embryonic stem cells at the Blastocyst stage of neural progenitor cells, isolated and purified, was able to fight Parkinson’s disease.

As soon as the news had spread, Greenpeace took action, and so the Patent Office in Germany canceled the registration of the patent, sparking the legal Brustle replication. The European Court is expressed only now and says: “From the moment of his human egg fertilization must all be considered as a human embryo, since fertilization is likely to start the process of developing a human being must also be recognized that the classification of human embryo unfertilized human egg even when it was implanted in a human cell nucleus and mature unfertilized human egg induced to divide and develop through parthenogenesis”.

The Court of Justice refers to Directive 98/44/EC on ‘protection of biotechnological inventions’: it may be the subject of patent application regarding the human embryo that has therapeutic or diagnostic purposes useful to the embryo itself, as it excludes any possibility of obtaining a patent for a process that undermines respect for human dignity.
The opinions of the scientific world is divided in defense of the German researcher and in favor of the EU ruling.

According to the director of the Institute of Bioethics of the Catholic University of Rome, Antonio is a Spanish long-ruling and hoped to be welcomed with great satisfaction because it says “to the fore the issue of ethical and legal status of the embryo”.

In favor of the sentence, even Bruno Dallapiccola, a geneticist and scientific director of the Hospital Bambino Gesù in Rome, declaring: “That is a decision of the EU common sense: there is no scientific evidence that when the sperm meets the egg of chemical modifications that are already beginning to initiate life, and then the embryo from the beginning to be regarded as a human life. Also you can not patent something that has created nature”.

Instead Carlo Alberto Redi, a geneticist at the University of Pavia, thinks that the decision of the Court of Justice is the result of a prejudice wrong and false ethics. “There are two fundamental errors in this view: first, the embryo obtained by nuclear transfer has no chance to develop, and secondly, in Europe there are frozen embryos to be destroyed and even the Catholic ethics can be d ‘ agreed that they preferred to be disposed of rather than used for research, “said Redi, arguing that the ruling will encourage researchers to move only the most tolerant countries like India, Brazil or the U.S..

Unlike other industrial uses of enzymes, medical and pharmaceutical applications thereof, generally require small amounts of highly purified enzymes. In part, this reflects the fact that for a enzyme be effective, should only be amended or compounds of interest contained in a complex physiological fluids or tissues.

Therapeutic enzyme:

This form of therapy, based on the administration of a specific enzyme to a patient, to produce a progressive improvement in the same, the main problem with this method is the body’s immune response which inactivates the compound incorporated. Also, if the target of an enzyme or a product obtained by enzymatic methods is administered to a patient, it is clear that the formula must contain the smallest possible amounts of foreign material to avoid side effects.

Genetic Defects:

Currently about one hundred fifty metabolic diseases have been attributed to specific enzyme defects. In several cases, the alteration is due to complete lack of the enzyme, while in others, the cause is the replacement for an isoenzyme partially inactive.

In theory, once known the defect, it should be possible to deliver the missing enzyme to patients and alleviate or eliminate symptoms of the disorder. Attempts to treat metabolic diseases inherited by the administration of exogenous enzymes have been only partially successful. The main problem is that the enzyme is incorporated into the body tends to accumulate in the liver and spleen.

The fact that the liposomes tend to accumulate preferentially in the liver is the most serious drawback to the use of this pathway in enzyme therapy. Similarly, other management methods also lead to an accumulation of enzymes in the liver and spleen, while too little of them, reach other organs. Genetic alterations such as cystic fibrosis elapses combined with pancreatic insufficiency, in these cases the pancreatic ducts are blocked and enzymes that play a vital role in normal digestion does not reach the intestine, leading to clinical symptoms of malnutrition.

Oral administration of pancreatic enzymes suitably protected against denaturation by stomach acid, helps to develop a normal digestion and thus adequate nutrition.

Control of neoplasms:

Intravenous administration of L-asparaginase for the treatment of certain neoplasms that affect blood cells has been used successfully, especially in the case of leucemia lymphocytic leukemia. After treatment with this enzyme collected data indicate a complete remission of the disease by up to 60% of patients. Other studies suggest that this enzyme may be useful in treating other cancers such as leukemia and related diseases.

The mechanism for the use of L-asparaginase in acute lymphocytic leukemia is based on the observation that certain tumor cells have a nutritional requirement for L-asparagine exogenous, while normal cells are able to synthesize this amino acid in situ.

Consequently, intravenous administration of the enzyme decreases blood levels of L-asparagine, depriving the abnormal cells of a vital nutrient and causing regression of the neoplasm. It was also suggested that the relatively high levels of L-aspartate produced in the enzymatic reaction can be toxic to tumor cells. A further advantage of this treatment is the high therapeutic index of enzymes, compared with alternative treatment that uses anti-leukemic chemicals.

The use given to the enzymes, initially as biological catalysts has been changing and diversified to be applied in various industries, today expands its usefulness in medicine, in specific areas of laboratory reagents exclusively for patients.

This gives humans the opportunity to dissociate olfactory perception and physical stimulation. As such, the binaural rivalry can offer a unique window into the state of consciousness both in healthy people sick. Related to this dissociation is a publication of these days when it unveils a new discovery: the brain, “smell” what you expect, regardless of physical stimulation.

How do you learn to distinguish between different smells?

In a study published in 2006 the researchers show that the brain learns to differentiate between similar smells through passive experience, shedding light on how we learn to identify thousands of smells from birth. The study also revealed for the first time how and where the brain modifies and updates information about smells.

When you have prolonged sensory experience with a smell, a person becomes an expert in the smells that are part of the same category. As a result of prolonged exposure to an odor a brain area known as orbitofrontal cortex (A region closely linked to the smell, emotions and motivation) showed an improved response to odors.

The brain identifies the source of the odor:

Apparently, the mammalian brain compares smells of each nostril to know where the smell comes in the same way that compares sounds enter through the ears to locate the source. It was thought that this was unlikely because the nostrils of some mammals, such as the mouse, for example, are very close as to receive different smells. The human brain compares the information of the two “noses” to turn smell information on spatial information.

The brain has a predictive power for odor:

Seeing roses before a person stops to smell, it is possible that the brain and sensory system was preparing for that familiar smell from the flowers. New research provides strong evidence that the brain uses to generate a predictive code templates “predictive” of specific odors, establishing a mental expectation of a scent before it reaches the nose.

Predictive templates have been studied in the visual system, but this is the first study to examine the evolution of space-time patterns of activity in the human olfactory cortex.

Predictive coding is important because it provides the animals, in this case human, an advantage for their behavior in the sense that they can react much faster and more accurately to stimuli from their environment.

The templates are specific to the odor olfactory:

The researchers were able to locate the pattern of brain activity before any smell came and found that, when the smell was the same as a previously presented, the pattern of activity was more highly correlated when the smell was different. The investigation confirmed the existence of predictive coding mechanisms in the olfactory system. The olfactory part observed, as a whole, formed templates that were very specific to the perceived odor.

The study, funded by the National Institute on Deafness and Other Communication Disorders in the U.S., has been published in the October 6 issue of the journal Neuron.